Author: Zhang, Xu; Ao, Zhujun; Bello, Alexander; Ran, Xiaozhuo; Liu, Shuiping; Wigle, Jeffrey; Kobinger, Gary; Yao, Xiaojian
Title: Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection Cord-id: qoz22q3i Document date: 2016_1_9
ID: qoz22q3i
Snippet: Currently, no approved antiviral therapeutic is available for treatment or prevention of Ebola virus (EBOV) infection. In this study, we characterized an EBOV-glycoprotein (GP) pseudotyped HIV-1-based vector system in different cell cultures, including human umbilical vein endothelial cells (HUVECs) and human macrophages, for the screening of anti-EBOV-GP agent(s). Based on this system, we demonstrated that an aqueous extract (CHPV) from the Chinese herb Prunella vulgaris displayed a potent inhi
Document: Currently, no approved antiviral therapeutic is available for treatment or prevention of Ebola virus (EBOV) infection. In this study, we characterized an EBOV-glycoprotein (GP) pseudotyped HIV-1-based vector system in different cell cultures, including human umbilical vein endothelial cells (HUVECs) and human macrophages, for the screening of anti-EBOV-GP agent(s). Based on this system, we demonstrated that an aqueous extract (CHPV) from the Chinese herb Prunella vulgaris displayed a potent inhibitory effect on EBOV-GP pseudotyped virus (EBOV-GP-V)-mediated infection in various cell lines, including HUVEC and macrophage. In addition, our results indicated that CHPV was able to block an eGFP-expressing Zaire ebola virus (eGFP-ZEBOV) infection in VeroE6 cells. The anti-EBOV activity of CHPV was exhibited in a dose-dependent manner. At a 12.5 μg/ml concentration, the CHPV showed a greater than 80% inhibition of EBOV-GP-V and eGFP-EBOV infections. Likewise, our studies suggested that the inhibitory effect of CHPV occurred by binding directly to EBOV-GP-Vs and blocking the early viral events. Interestingly, our results have shown that CHPV was able to enhance the anti-EBOV activity of the monoclonal antibody MAb 2G4 against EBOV-GP. Overall, this study provides evidence that CHPV has anti-EBOV activity and may be developed as a novel antiviral approach against EBOV infection.
Search related documents:
Co phrase search for related documents- absence presence and active ingredient: 1
- absence presence and addition time: 1
- absence presence and adherent cell: 1
- absence presence and low concentration: 1, 2, 3
- absence presence and low toxicity: 1, 2
- absence presence and luciferase gene: 1, 2, 3, 4
- absence presence and lung carcinoma: 1
- absence presence and lysis buffer: 1, 2, 3, 4, 5
- absence presence and macrophage observe: 1
- absence presence and macrophage study: 1
- action antiviral mechanism and low concentration: 1
- action antiviral mechanism and low cytotoxicity: 1
Co phrase search for related documents, hyperlinks ordered by date